Scotiabank lifts target for AbbVie stock from USD 280.00 to USD 320.00
Published on 10/16/2026 at 15:02 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- Scotiabank analyst Louise Chen raised the AbbVie target from USD 280.00 to USD 320.00 on October 6, 2026.
- AbbVie will announce third-quarter 2026 results on October 30, 2026, before the market opens.
- AbbVie stock costs EUR 252.75 at Lang & Schwarz on October 16, 2026 at 3:00 p.m. CEST.
- AbbVie had a P/E of 79.84 and a market capitalization of USD 500.8 billion as of October 15, 2026.
Scotiabank analyst Louise Chen raised the price target for AbbVie from USD 280.00 to USD 320.00 on October 6, 2026, while keeping an Outperform rating, according to Markets Insider. Against the Nasdaq price of USD 283.38 on October 15, 2026, the new target stood 12.92 percent higher. AbbVie was trading at EUR 252.75 at Lang & Schwarz on October 16, 2026 at 3:00 p.m. CEST.
October 30 results date
AbbVie is scheduled to announce its third-quarter 2026 financial results before the market opens on October 30, 2026. The company also scheduled an earnings call for 8:00 a.m. Central time that day, according to AbbVie. The date gives investors a defined next checkpoint after the recent target revisions.
Stock near the yearly high
On October 15, 2026, AbbVie last traded at USD 283.38 on the Nasdaq at 4:00 p.m. ET. Its 52-week range was USD 190.75 to USD 291.33, leaving the stock 2.73 percent below the high. The same quotation showed a market capitalization of USD 500.8 billion and an average volume of 4,843,984 shares.
Valuation and dividend yield
AbbVie carried a P/E ratio of 79.84 and a dividend yield of 2.00 percent as of October 15, 2026. The valuation sits alongside a USD 320.00 target from Scotiabank and a separate USD 300.00 target from JPMorgan dated October 8, 2026, as listed by MarketBeat.
Comparison with peers
AbbVie Inc.: P/E 79.84, market capitalization USD 500.8 billion.
Bristol-Myers Squibb Company (NYSE, USD): plus 2.18 percent, P/E 13.34, market capitalization USD 123.7 billion.
Merck & Co., Inc. (NYSE, USD): minus 1.37 percent, P/E 116.28, market capitalization USD 358.6 billion.
The euro quote in context
AbbVie stock stood at EUR 252.75 at Lang & Schwarz on October 16, 2026 at 3:00 p.m. CEST. The Nasdaq last price was USD 283.38 on October 15, 2026 at 4:00 p.m. ET, while the 52-week high was USD 291.33.
The further course of trading is shown by the continuously updated real-time quote of AbbVie stock.
AbbVie stock facts
- Company: AbbVie Inc.
- ISIN: US00287Y1091
- Ticker: ABBV
- Primary exchange: NYSE
- Price Lang & Schwarz (as of October 16, 2026, 3:00 p.m. CEST): EUR 252.75
- Market capitalization: USD 500.8 billion (as of October 15, 2026)
- 52-week range: USD 190.75-291.33 (as of October 15, 2026)
- P/E ratio: 79.84 (as of October 15, 2026)
- Dividend yield: 2.00 percent (as of October 15, 2026)
Market context: Market report S&P 500.
